<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t78v4k23qxt5 st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" tabindex="0" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file â€¢ PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="Antimicrobials and Chemotherapy.pdf">Antimicrobials and Chemotherapy.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">7.0MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> Antimicrobials and Chemotherapy.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anticancer-drugs">Anticancer Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anticancer-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lecturer-geoffrey-9th-december-2024-kmtc-nyahururu-campus">Lecturer: Geoffrey 9th December 2024 KMTC-Nyahururu Campus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lecturer-geoffrey-9th-december-2024-kmtc-nyahururu-campus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="learning-objectives">Learning Objectives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#learning-objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>By the end of this lesson the student should be able to:</li>
<li>Describe the pathogenesis of cancer</li>
<li>Describe the drugs used in cancer management and their side effects.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="introduction-to-anti-cancers">Introduction to anti-cancers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#introduction-to-anti-cancers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Cancer is uncontrolled multiplication and spread of abnormal cells of the body.</li>
<li>Second common cause of death in the world.</li>
<li>In developed world lung and colon cancers are the leading then followed by breast and prostate cancers.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="introduction-to-anti-cancers">Introduction to anti-cancers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#introduction-to-anti-cancers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Benign and cancer are both uncontrolled multiplication of the cells however, the latter is invasive and spreads to other parts of the body.</li>
<li>Inherited and acquired gene mutations is linked to tumorgenesis</li>
<li>Cancer is treated by use of 3 modalities namely: surgical excision, irradiation and drug therapy (chemotherapy)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pathogenesis-of-cancer">Pathogenesis of cancer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathogenesis-of-cancer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Cancer have four characteristics that distinguish them from the normal cells. Which are:</li>
</ul>
<ol>
<li>Uncontrolled proliferation</li>
<li>De-differentiation and loss of function</li>
<li>Invasiveness</li>
<li>Metastasis</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pathogenesis-of-cancer">Pathogenesis of cancer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathogenesis-of-cancer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Cancers cells start to form due to exposure to viruses or carcinogens (tobacco, asbestos) which causes DNA mutations.</li>
<li>In breast cancer for example, women inherit a defective copy of suppressor gene BRCA1 &amp; BRCA2.</li>
<li>Exposure to carcinogens for a long time, increase the like hood of developing genetic mutation that results to cancer.</li>
<li>There is activation of proto-oncogenes to oncogenes (proto-oncogenes are genes that control cell division, apoptosis and differentiation).</li>
</ul>
<p><img src="data:image/jpeg;base64,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" alt="img-0.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemicals-viruses-irradiation-etc">Chemicals, viruses, irradiation, etc.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemicals-viruses-irradiation-etc" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li><strong>Acquired mutations</strong></li>
<li><strong>Inherited mutations</strong></li>
<li><strong>Altered gene expression</strong></li>
<li><strong>Proto-oncogenes</strong>
<ul>
<li><strong>Oncogenes</strong> <em>sis, erbB, ras, myc,</em> <strong>gene for cyclin D, etc.</strong></li>
</ul>
</li>
<li><strong>Decreased expression of tumour suppressor genes:</strong> <em>p53, Rb1, etc.</em></li>
<li><strong>Other factors</strong></li>
<li><strong>Uncontrolled cell proliferation, de-differentiation</strong></li>
<li><strong>Decreased apoptosis, alterations in telomerase</strong></li>
<li><strong>Development of primary tumour</strong></li>
<li><strong>Production of metalloproteinases etc.</strong></li>
<li><strong>Invasion of nearby tissue by tumour cells</strong></li>
<li><strong>Angiogenesis</strong></li>
<li><strong>Metastasis</strong></li>
<li><strong>Development of secondary tumours</strong></li>
</ul>
<p><em>January 16, 2025</em></p>
<p><em>Fig. 56.2 Simplified outline of the genesis of cancer. The</em></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pathogenesis-of-cancer">Pathogenesis of cancer<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pathogenesis-of-cancer" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>There is also inactivation of tumor suppressor genes (antioncogenes) and mutations which is caused by viral infections or chemical carcinogens.</li>
<li>Common gene mutations are; point mutations, gene amplification or chromosomal dislocations.</li>
<li>Cancer cells escape the mechanism that regulate cell division and tissue growth. This causes uncontrolled proliferation.</li>
<li>In cancerous cells there is also resistance to apoptosis (programmed cell death).</li>
<li>Cancer cells de-differentiate this means that cancer cells have no function they perform in the body.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="general-effects-of-cancer-therapy">General effects of cancer therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-effects-of-cancer-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Bone marrow toxicity (bone 6. Sterility marrow suppression)</li>
<li>Impaired wound healing</li>
<li>Loss of hair (alopecia)</li>
<li>Depression of growth in children</li>
<li>Damage the gastrointestinal 10. Severe nausea and vomiting epithelium</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classes-of-cancer-therapy">Classes of cancer therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classes-of-cancer-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Cytotoxic drugs e.g. alkylating agents (imped replication), antimetabolites, cytotoxic antibiotics, plant derivatives (vinca alkaloids)</li>
<li>Hormones e.g. glucocorticoids, estrogen</li>
<li>Protein kinase inhibitors</li>
<li>Monoclonal antibodies</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-alkylating-agents">1. Alkylating Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-alkylating-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>These drugs form covalent bond with nucleophilic substance e.g. DNA</li>
<li>They form carbonium ion which is highly reactive with hydroxyl, amine or sulfhydryl.</li>
<li>Insertion of alkyl group forms cross-links between the strands preventing separation which is necessary for replication.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-alkylating-agents">1. Alkylating Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-alkylating-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>All alkylating agents causes bone marrow depression, sterility especially men, git disturbances, and hair loss.</li>
<li>Examples are; nitrogen mustards, nitrosoureas, platinum compounds</li>
<li>Procarbazine inhibits DNA &amp; RNA synthesis</li>
<li>Others are; hydroxycarbamide, decarbazine, temozolomide</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-alkylating-agents">1. Alkylating Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-alkylating-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Platinum compounds: cisplatin, carboplastin</li>
<li>Cisplastin has a central platinum atom surrounded by 2 chlorine atoms and 2 ammonia groups.</li>
<li>When dissolves in water, it dissociates into <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">âˆ’</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">âˆ’</span></span></span></span></span></span></span></span></span></span></span></span></span>which interacts with DNA.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-alkylating-agents">1. Alkylating Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-alkylating-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Cisplastin is used to treat solid tumors of the ovary and testes.</li>
<li>Given slow intravenous or as an infusion.</li>
<li>Side effects: nephrotoxicity, myelotoxicity, severe nausea and vomiting, peripheral neuropathy, tinnitus, hearing loss, hyperuricemia and anaphylactic reactions.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-alkylating-agents">1. Alkylating Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-alkylating-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Nitrogen mustards form ethylene immonium highly reactive compound which interacts with DNA.</li>
<li>Example of nitrogen mustards is cyclophosphamide which is metabolized in the liver by P450 into active form.</li>
<li>Cyclophosphamide is given orally or intravenously. It causes nausea and vomiting, bone marrow suppression and hemorrhagic cystitis.</li>
<li>Other examples of nitrogen mustards are; bendramustine, chlorambucil, and melphan.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1-alkylating-agents">1. Alkylating Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-alkylating-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Nitrosoureas- this include lomustine and carmustine.</li>
<li>They are lipid soluble and cross the blood-brain barrier hence used to treat the tumors of the brain and meninges.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2-antimetabolites">2. Antimetabolites<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-antimetabolites" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Folate antagonist e.g. methotrexate</li>
<li>Folate is essential in formation of purine nucleotide and thymidyalte which form the DNA.</li>
<li>Folate antagonist interfere with thymidylate synthesis.</li>
<li>Methotrexate block the enzyme dehydrofolate reductase required in formation of tetrahydrofolate (FH4) required for purine and DNA synthesis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2-antimetabolites">2. Antimetabolites<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-antimetabolites" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Methotrexate is given orally, intravenously or intramuscularly.</li>
<li>It is taken up by the cells and transported by folate transport system and is metabolized to polyglutamate derivatives.</li>
<li>Methotrexate is also used in treatment of psoriasis, rheumatoid arthritis and other autoimmune diseases.</li>
<li>Methotrexate adverse effects are; bone marrow suppression, nephrotoxicity, pneuomonitis, damage to GIT epithelium.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2-antimetabolites">2. Antimetabolites<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-antimetabolites" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Pyridine analogues e.g. - fluorouracil which inhibits DNA synthesis and is given parenterally and it causes myelotoxicity and GIT epithelial damage.</li>
<li>Other drugs are; capecitabine, tegafur, cytarabine (cytosine arabinoside), gemicitabine, azacitidine and decitabine.</li>
<li>Purine analogues are; cladribine, clofarabrine, fludarabine, pentostatin, captopurine,</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="3-cytotoxic-antibiotics">3. Cytotoxic Antibiotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-cytotoxic-antibiotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Have direct action on DNA and should not be given together with radiotherapy because of high toxicity.</li>
<li>Examples; doxorubicin, idarubicin, daunorubicin, epirubicin and mitoxantrone (derivative).</li>
<li>
<ol>
<li>Doxorubicin inhibits DNA and RNA synthesis through inhibition of topoisomerase II.</li>
</ol>
</li>
<li>Doxorubicin is given through infusion and its side effects are; extravasation causes necrosis, cardiac damage, heart failure.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="3-cytotoxic-antibiotics">3. Cytotoxic Antibiotics<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-cytotoxic-antibiotics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<ol start="2">
<li>Dactinomycin- inserts between guanosine-cytosine pairs interfering with RNA polymerase from transcription. Used to treat pediatric cancers.</li>
</ol>
</li>
<li>
<ol start="3">
<li>Bleomycins- metal-chelating glycoprotein antibiotics that degrades preformed DNA. Chelating occurs through ferrous iron and interaction with oxygen forming superoxide radicals. Used to treat germline cancers. Its less toxic to bone marrow however other serious side effects are; pulmonary fibrosis and allergic reactions.</li>
</ol>
</li>
<li>
<ol start="4">
<li>Mitomycin- functions as bifunctional alkylating agent at guanine nucleus. It degrades DNA by formation of free radicals. It causes kidney damage, lung fibrosis and myelosuppression.</li>
</ol>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="4-plant-derivatives">4. Plant Derivatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-plant-derivatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<ol>
<li>Vinca alkaloids- vincristine, vinblastine, vindesine, vinflumine (fluorinated) and vinorelbine (semisynthetic vinca alkaloids).</li>
</ol>
</li>
<li>MOA; they bind the tubulin preventing polymerization into microtubules therefore, it inhibits spindle fibers formation and arrest of metaphase.</li>
<li>They also inhibits other cellular activities that require microtubules like leucocyte phagocytosis.</li>
<li>Adverse effects; vincristine causes mild myelosuppression, neurotoxic, paraesthesia, abdominal pain and weakness.</li>
<li>Vinblastine is less neurotoxic, causes leuocopenia, reversible hair loss</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="4-plant-derivatives">4. Plant Derivatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-plant-derivatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<ol start="2">
<li>Paclitaxel and related compounds e.g. paclitaxel, docetaxel and cabazitaxel.</li>
</ol>
</li>
<li>Derived from naturally occurring pacific yew tree (Taxus spp).</li>
<li>MOA: interferes with microtubules function and are given intravenous infusion. Used to treat breast and lung cancer.</li>
<li>Carboplastin and paclitaxel are used in combination to treat ovarian cancer.</li>
<li>Side effects: bone marrow suppression, neurotoxicity, hypersensitivity reaction and fluid retention causing edema.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="4-plant-derivatives">4. Plant Derivatives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-plant-derivatives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<ol start="3">
<li>Camptothecins e.g. irinotecan and tiopotecan are derived from camptotheca acuminata tree. They interfere with topoisomerase I. They have less side effects like reversible bone marrow suppression and diarrhea.</li>
</ol>
</li>
<li>
<ol start="4">
<li>Etoposide- inhibits mitochondrion function, nucleoside transport and topoisomerase II. Causes nausea and vomiting, myelosuppression and hair loss.</li>
</ol>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="5-hormones">5. Hormones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-hormones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Some tumors originate from hormone sensitive tissues like the breast, prostate, uterus and ovaries.</li>
<li>These tumors are hormone dependent because they have hormone receptors in there cells.</li>
<li>Treatment targets hormone agonist, antagonist or inhibition of hormone synthesis.</li>
<li>
<ol>
<li>Glucocorticoids- prednisolone is used in treatment of lymphomas and leukemia. It inhibits lymphocyte proliferation. Dexamethasone is used to treat brain tumors</li>
</ol>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="5-hormones">5. Hormones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-hormones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<ol start="2">
<li>Oestrogen- Diethylstilbestrol occasionally used in treatment of androgen dependent prostatic tumors.</li>
</ol>
</li>
<li>
<ol start="3">
<li>Progestogens- megestrol, medroxyprogesterone and norehisterone are used in treatment of endometrial cancer.</li>
</ol>
</li>
<li>
<ol start="4">
<li>Gonadotropin releasing hormone analogues e.g. goserelin, buserelin, triptorelin used in treatment of breast cancer and prostate cancer. Degaralix is gonadotropin releasing hormone antagonist used to treat prostate cancer.</li>
</ol>
</li>
<li>
<ol start="5">
<li>Somatostatin analogues- octreotide and lanreotide treat neuroendocrine tumors e,g glucagonomas, carcinoid tumors, gastrinomas</li>
</ol>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="6-hormones-antagonist">6. Hormones Antagonist<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#6-hormones-antagonist" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Antiestrogens e.g. tamoxifen, toremifene which block estrogen receptors in tumors which are hormone-dependent like breast cancer.</li>
<li>Unwanted effects are; endometrial cancer, thromboembolism.</li>
<li>Aromatase inhibitors block estrogen formation from androgens in the adrenal cortex examples are; anastrozole, letrozole and exemestane.</li>
<li>Antiandrogen- examples flutamide, cyproterone and bicalutamide may be combine with other agents to treat prostate cancer.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="summary-of-anti-cancer-agents-hormones">Summary of anti-cancer agents: Hormones<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#summary-of-anti-cancer-agents-hormones" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hormones or their antagonists are used in hormone sensitive tumors.</li>
<li>Glucocorticoids- leukemia and lymphomas</li>
<li>Tamoxifen- breast tumors</li>
<li>Gonadotropin releasing hormone analogue- prostate and breast tumors.</li>
<li>Antiandrogens- prostate cancer</li>
<li>Aromatase inhibitors- postmenopausal breast cancer.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="7-monoclonal-antibodies">7. Monoclonal Antibodies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#7-monoclonal-antibodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Example are; rituximab used with other agents to treat Blymphomas. Given through infusion and can cause hypotension, rashes, fever</li>
<li>Trastuzumab-bind to oncogene protein slowing proliferation. Used in treatment of breast cancer.</li>
<li>Bevacizumab- neutralize vascular endothelial growth factor (VEGF) used to treat colorectal cancer.</li>
<li>Protein kinase inhibitors e.g. imatinib</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="summary-of-monoclonal-antibodies-protein-kinase-inhibitors">Summary of Monoclonal Antibodies &amp; Protein kinase inhibitors.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#summary-of-monoclonal-antibodies-protein-kinase-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Monoclonal antibodies <em>inhibit tumor cells proliferation and growth</em>.</li>
<li>For example <strong>trastuzumab</strong> neutralizes the growth factors of some tumor cells.</li>
<li>Protein kinase inhibitors prevent down-stream signaling triggered by growth factors e.g. <strong>imatinib</strong>.</li>
<li>Some monoclonal acts directly on lymphocyte cells causing lysis e.g. <strong>rituximab</strong>.</li>
</ul>
<p><em>January 16, 2025</em></p>
<p><em>30</em></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanisms-of-anti-cancer-drugs-resistance">Mechanisms of Anti-cancer Drugs Resistance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanisms-of-anti-cancer-drugs-resistance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1 Decreased accumulation of the drug in the cells.
2 Decrease in drug taken up by the cells e.g. methotrexate
3 Insufficiency activation of the drug e.g. fluorouracil should be converted to FDUMP.</p>
<p>4 Increase in inactivation of the drug e.g. cytarabine
5 Increased concentration of the target enzyme
6 Decreased requirement of the substrate
7 Increased utilization of alternative metabolic pathways
8 Rapid repair of drug-induced DNA damage e.g. alkylating agents
9 Altered activity of target e.g. modified topoisomerase II (Doxorubicin)
10 Jan Mutation of various genes</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="the-end">The End<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-end" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antihelminthics">ANTIHELMINTHICS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antihelminthics" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>14/12/2025 antihelminths by mutiso 68 @gmail.com 1</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anthelmintic-drugs">ANTHELMINTIC DRUGS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anthelmintic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="helminth-infections">Helminth Infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#helminth-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Tapeworms ( cestodes)</li>
<li>Intestinal round worms ( nematodes)</li>
</ol>
<p>Ascaris, pinworm ,whipworm, strongyloides, ancylostoma ( hookworm )
3. Flukes(Trematodes): schistosoma(mansoni(in feaces, rare in urine), heamatobium(in urine, rarely in feaces) &amp; japonicum (in feaces)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anthelminthic-drugs">Anthelminthic Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anthelminthic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Generally these act by either one of these mechanism:</li>
</ul>
<ol>
<li>Causing paralysis of the worm</li>
<li>Damaging the worm leading to partial digestion or rejection by immune mechanisms</li>
<li>Interfere with the metabolism of the worm
*Worms or larvae live in tissues of host body like muscles, viscera, menninges, subcutaneous tissues</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nematodes">Nematodes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nematodes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Examples: Ascaris, pinworm ,whipworm, strongyloides, ancylostoma ( hookworm)</li>
<li>They cause infections of the intestine as well as the blood and tissues</li>
<li>Drugs used in their management include:</li>
<li>Diethylecarbamazine</li>
<li>Ivermectin</li>
<li>Mebendazole</li>
<li>Pyrantel pamoate</li>
<li>Thiabendazole</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="trematodes-flukes">Trematodes/flukes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#trematodes-flukes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs for management of trematodes: praziquantel</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cestodes-tapeworms">Cestodes (tapeworms)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cestodes-tapeworms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drugs-for-cestodes">Drugs for cestodes:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-for-cestodes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Albendazole
Niclosamide
Include:</p>
<ul>
<li>
<p>Taenia saginata or the beef tapeworw) (intermediate host cow)and</p>
</li>
<li>
<p>Taenia solium or pork tapeworm( I.H pig)</p>
</li>
<li>
<p>Taenia diphyllobothrium or fish tapeworm(IH fish)</p>
</li>
<li>
<p>Lifecycle in three stages: the egg, larvae and adult worm</p>
</li>
<li>
<p>Adults found in the intestines of definitive host-human</p>
</li>
<li>
<p>They absorb food directly from the host</p>
</li>
<li>
<p>Adult worm lay eggs and they are lost in feaces and picked by the intermediate host during feeding</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="benz-imidazoles">Benz-imidazoles<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#benz-imidazoles" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Include drugs like:</li>
<li>Mebendazole, albendazole, triclabendazole, metronidazole, tinidazole, thiabendazole</li>
<li>Used to treat intestinal helminthes infections, especially those caused by nematodes and
cestodes</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of action:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Inhibits the polymerization of tubulin into microtubules</li>
<li>This inhibition prevents cellular division and the absorption of glucose in its intestines</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="albendazole">ALBENDAZOLE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#albendazole" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>A broad-spectrum oral anthelmintic, is the drug of choice or RT of hydatid disease and cysticercosis</li>
<li>Also used in the treatment of pinworm and hookworm infections, ascariasis, trichuriasis, and strongyloidiasis</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pk">PK<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pk" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Erratically absorbed after oral administration</li>
<li>Increased with a fatty meal</li>
<li>Rapidly undergoes first-pass metabolism in the liver to the active metabolite albendazole sulfoxide</li>
<li>It reaches variable maximum plasma concentrations about 3 hours following a 400 mg oral dose</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pk-ct">PK ct.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pk-ct" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Has a plasma half-life is 8-12 hours</li>
<li>The sulfoxide is mostly protein-bound,</li>
<li>Distributes well to tissues, and enters bile, cerebrospinal fluid, and hydatid cysts</li>
<li>Metabolites are excreted in the urine</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism Of Action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Inhibits microtubule synthesis by binding to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>Î²</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">Î²</span></span></span></span></span> tubulin</li>
<li>Inhibits mitochondrial reductase causing reduced glucose transport</li>
<li>Intestinal parasites are immobilized and die slowly</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="moa">MOA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#moa" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Has larvicidal effects in hydatid disease, cysticercosis, ascariasis, and hookworm infection</li>
<li>Has ovicidal effects in ascariasis, ancylostomiasis, and trichuriasis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-uses">Clinical uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Used on empty stomach when used against intraluminal parasites but with a fatty meal when used against tissue parasites.</li>
</ul>
<ol>
<li>In ascariasis, trichuriasis, hookworm, pin worm infections : children over 2 years &amp; adults (single dose 400 mg , repeated for 2-3 day in heavy ascaris infection. For 2 wks for pin worm infection</li>
<li>Hydatid diseases:
drug of choice for medical therapy&amp; adjunctive to surgical removal or aspiration of cysts.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="albendazole-con">Albendazole (con')<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#albendazole-con" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol start="3">
<li>Neurocysticercosis:</li>
</ol>
<p>Used with corticosteroid to decrease the inflammation caused by dying organism and it also reduces the duration of course for 21 days
4. Other infections: Drug of choice in cutaneous and visceral larva migrans, intestinal capillariasis, giardiasis &amp; taeniasis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-uses-ct">clinical uses ct.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-uses-ct" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol start="3">
<li>Neurocysticercosis:</li>
</ol>
<p>Used with corticosteroid to decrease the inflammation caused by dying organism and it also reduces the duration of course for 21 days
4. Other infections: Drug of choice in cutaneous and visceral larva migrans, intestinal capillariasis, giardiasis &amp; taeniasis.</p>
<ul>
<li>
<p>Albendazole is the drug of choice in the treatment of cutaneous larva migrans ( 400 mg daily for 3 days),</p>
</li>
<li>
<p>Visceral larva migrans ( 400 mg twice daily for 5 days),</p>
</li>
<li>
<p>Intestinal capillariasis ( 400 mg daily for 10 days), microsporidial infections ( 400 mg twice daily for 2 weeks or longer)</p>
</li>
<li>
<p>It also has activity against trichinosis ( 400 mg twice daily for 1-2 weeks) and clonorchiasis ( 400 mg twice daily for 1 week)</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrs">ADRs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Used for 1-3 days, albendazole is nearly free of significant adverse effects</p>
</li>
<li>
<p>Mild and transient epigastric distress, diarrhea, headache, nausea, dizziness, lassitude, and insomnia can occur</p>
</li>
<li>
<p>In long-term use for hydatid disease, albendazole is well tolerated, but it can cause abdominal distress, headaches, fever, fatigue, alopecia, increases in liver enzymes, and pancytopenia (reduction of blood cell count - RBC, WBC &amp; platelets).</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="caution">Caution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#caution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Should not be given to patients with known hypersensitivity to other benzimidazole drugs or to those with cirrhosis</li>
<li>The safety of albendazole in pregnancy and in children younger than 2 years of age has not been established</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mebendazole"><strong>MEBENDAZOLE</strong><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mebendazole" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Synthetic benzimidazole</li>
<li>Wide spectrum and low incidence of adverse effects</li>
</ul>
<p><strong>Mechanism of action:</strong></p>
<ul>
<li>Inhibits microtubule synthesis.</li>
<li>It kills hookworm, pin worm, ascaris and trichuris eggs</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mebendazole-ct">Mebendazole ct.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mebendazole-ct" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Effective against a wide spectrum of nematodes</li>
<li>Drug of choice in treatmnent of infections by whipworm(trichuris trichura), pinworm(enterobius vermicularis), and hookworm(necator americanas and ancylostoma duodenale)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="moa">MOA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#moa" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Bind and interfere with the synthesis of the parasite microtubules and by decreasing glucose uptake.</li>
<li>Affected parasite are then expelled with the faeces</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pk">Pk<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pk" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Little of the oral dose is absorbed, therefore Free of toxicity</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="caution">Caution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#caution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Its embryotoxic and teratogenic and therefore Contraindicated in pregnancy</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pyrantel-pamoate">Pyrantel pamoate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pyrantel-pamoate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>A Broad spectrum: For treatment of infections by roundworms, pinworms, and hookworms</li>
<li>Poorly absorbed orally, its effect limited to the GIT</li>
<li>MOA: act as a depolarizing neuromuscular blocking agent, that result in the worm paralysis which is then expelled from the host</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-uses">Clinical uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Very effective against luminal organisms( mature or immature forms)</li>
<li>Not effective against migratory stages in the tissues or against ova</li>
<li>Given orally with or without food</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects">Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Infrequent mild transient GI disturbance, drowsiness, headache ,insomnia, Rash ,fever</li>
</ul>
<p>Contraindications &amp; Cautions</p>
<ul>
<li>Should be used with caution in</li>
<li>liver dysfunction</li>
<li>Pregnancy</li>
<li>Children under 2 years of age</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adr">ADR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Mild:</li>
<li>nausea</li>
<li>Vomiting and</li>
<li>Diarrhoea</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="thiabendazole">Thiabendazole<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thiabendazole" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>A systemic benzimindazole</p>
</li>
<li>
<p>Effective against thread worm(strongyloides stercoralis), strongyloides cutaneous larva migrants and trichinosis (trichinella spiralis)</p>
</li>
<li>
<p>Readily absorbed on oral administration</p>
</li>
<li>
<p>Half-life of 1-2 hrs</p>
</li>
<li>
<p>Completely metabolized in liver and 90% is excreted in urine</p>
</li>
<li>
<p>Can also be absorbed through skin</p>
</li>
<li>
<p>Similar to other benzimidazoles</p>
</li>
<li>
<p>It is ovicidal for some parasites</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-uses">Clinical uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Should be given after meals and tablets should be chewed</li>
<li>Strongyloidal infections &amp; cutaneous larva migrans</li>
<li>Thiabendazole cream available for topical application</li>
<li>Drug also given orally for 2 days</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="more-toxic-than-other-benzamidazoles">More toxic than other benzamidazoles<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#more-toxic-than-other-benzamidazoles" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Potentially toxic: toxicities include: dizziness, anorexia, nausea, and vomiting
<ul>
<li>CNS symptoms</li>
<li>Erythema multiforme and Stevens-Johnson syndrome</li>
</ul>
</li>
<li>Irreversible liver failure</li>
<li>Not used in young children, pregnancy, hepatic and renal diseases</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diethylcarbamazine">Diethylcarbamazine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diethylcarbamazine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Drug of choice for treatment of filariasis caused by wuchereria bancrofti</li>
<li>MOA: immobilize the organism, there surface membrane undergo alterations and become susceptible to the host defence</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pk">PK<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pk" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Rapidly absorbed after oral administration
Partially metabolized
Excreted in urine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="adrs">ADRs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Mild, due to the dying parasite that affect the skin; pruritus, wheals, but can also be systemic</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-for-treatment-of-trematodes">DRUGS FOR TREATMENT OF TREMATODES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-for-treatment-of-trematodes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Praziquantel</li>
<li>Agent of choice in treatment of schistosomiasis</li>
<li>MOA increase permiability of the cell membrane to calcium causing contracture and paralysis of the organism</li>
</ul>
<p>PK</p>
<ul>
<li>Rapidly absorbed after oral administration</li>
<li>Distribute to CSF</li>
<li>Its extensively metabolized to an inactive metabolite, resulting in a short life</li>
<li>Excreted in urine</li>
</ul>
<p>ADR</p>
<ul>
<li>GIT disturbances, drowsiness, dizziness, malaise, and anorexia</li>
<li>Not recommended for pregnant, or nursing mothers</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-for-treatment-of-cestodes-tapeworms">Drugs for treatment of cestodes (tapeworms)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-for-treatment-of-cestodes-tapeworms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="niclosamide">Niclosamide<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#niclosamide" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Drug of choice for most cestodes</li>
<li>Second-line drug for treatment of most tapeworm infections</li>
<li>MOA: inhibit parasite mitochondria anaerobic phosphorilation thus kill the worm</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-uses">Clinical Uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Treatment of most forms of tapeworms</li>
<li>Not effective against cysticercosis or hydatic disease</li>
<li>Given in the morning on empty stomach</li>
<li>Poorly absorbed from gut</li>
<li>Excreted in urine</li>
<li>Purgative is necessary to purge all dead segments&amp; prevent liberation of ova</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects-contraindications">Adverse effects &amp; Contraindications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects-contraindications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Mild ,infrequent and transitory GI disturbance</li>
<li>Alcohol consumption should be avoided</li>
<li>Not indicated in children under 2 years of age or in pregnancy.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="piperazine">PIPERAZINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#piperazine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Only recommended for the treatment of ascariasis</li>
<li>cure rate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> for 2 days treatment</li>
<li>Readily absorbed orally and excreted mostly unchanged in urine</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Causes paralysis of ascaris by blocking acetylcholine at myoneural junction, the live worms expelled by normal peristalsis</p>
<ul>
<li>Treatment is continued for 3-4 days or repeated after one week in case of heavy infections.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects">Adverse Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>GI disturbance</li>
<li>Neurotoxicity ,allergic reactions</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications">Contraindications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Epilepsy or a history of epilepsy</li>
<li>Impaired liver or kidney functions</li>
<li>Pregnancy</li>
<li>Chronic neurologic disease</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimycobacterial">ANTIMYCOBACTERIAL<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimycobacterial" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>2018</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="introduction">Introduction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#introduction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Mycobacteria are intrinsically resistant to most antibiotics
Reasons:</p>
<ol>
<li>
<p>They grow slowly compared with other bacteria- antibiotics that are most active against growing cells are relatively ineffective</p>
</li>
<li>
<p>Mycobacterial cells can also be dormant and thus completely resistant to many drugs or killed only very slowly</p>
</li>
<li>
<p>The lipid-rich mycobacterial cell wall is impermeable to many agents</p>
</li>
<li>
<p>Mycobacterial species are intracellular pathogens, and organisms residing within macrophages are inaccessible to drugs that penetrate these cells poorly</p>
</li>
<li>
<p>Mycobacteria are notorious for their ability to develop resistance</p>
</li>
</ol>
<ul>
<li>
<p>â˜ Combinations of two or more drugs are required to overcome these obstacles and to prevent emergence of resistance during the course of therapy</p>
</li>
<li>
<p>â˜ Response of mycobacterial infections to chemotherapy is slow, and treatment must be administered for months</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs">Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They are classified into 1st line and 2nd line therapy
First-line agents are superior in efficacy and possess an acceptable degree of toxicity</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="1st-line-therapy">1st line therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1st-line-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>They include:
<ul>
<li><strong>Isoniazid (INH)</strong></li>
<li><strong>Rifampin (or other rifamycin)</strong></li>
<li><strong>Pyrazinamide</strong></li>
<li><strong>Ethambutol</strong></li>
<li><strong>Streptomycin</strong></li>
</ul>
</li>
<li>Isoniazid and rifampin are the two most active drugs</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2nd-line-therapy">2nd line therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2nd-line-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>They are more toxic and less effective
Are usually considered only In case of :
(1) Resistance to first-line agents
(2) Failure of clinical response to conventional therapy
(3) Serious treatment-limiting adverse drug reactions
(4) When expert guidance is available to deal with the toxic effects</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2nd-line-therapy">2nd line therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2nd-line-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>They include:
<ul>
<li>Ethionamide</li>
<li>Capreomycin</li>
<li>Cycloserine</li>
<li>Aminosalicylic Acid (PAS)
<ul>
<li>Kanamycin &amp; Amikacin</li>
<li>Fluoroquinolones</li>
<li>Thiacetazone</li>
<li>Rifabutin</li>
<li>Rifapentine</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>NB//</p>
<p>â˜ In practice, therapy is initiated with a four-drug regimen of isoniazid, rifampin, pyrazinamide, and either ethambutol or streptomycin</p>
<p>ANTIMYCOBACTERIA 2018 by urbanus mutiso 14/12/2025</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="rifampin">RIFAMPIN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rifampin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>MOA: Binds to the beta subunit of bacterial DNA-dependent RNA polymerase and thereby inhibits RNA synthesis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pk">PK:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pk" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Well absorbed after oral administration
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Excreted mainly through the liver into bile
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Undergoes enterohepatic circulation
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Bulk is excreted as a deacylated metabolite in feces and a small amount in the urine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="140dc2cb"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span><span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#140dc2cb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Dosage adjustment for renal or hepatic insufficiency is not necessary.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Usual doses result in serum levels of 5-7 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mcg} / \mathrm{mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">mL</span></span></span></span></span></span></p>
<p>Distributed widely in body fluids and tissues.</p>
<p>Relatively highly protein-bound,</p>
<p>Adequate CSF concentrations achieved only in the presence of meningeal inflammation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-uses">Clinical uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>Mycobacterial infections: rifampin, 600 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi><mo stretchy="false">(</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{d}(10 \mathrm{mg} / \mathrm{kg} / \mathrm{d})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span><span class="mopen">(</span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord mathrm">d</span><span class="mclose">)</span></span></span></span></span> orally, coadministered with isoniazid to avoid emergence of resistance</p>
</li>
<li>
<p>An oral dosage of 600 mg twice daily for 2 days can eliminate meningococcal carriage</p>
</li>
<li>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> for 4 days, is used as prophylaxis in contacts of children with Haemophilus influenzae</p>
</li>
<li>
<p>Combined with a second agent it is used to eradicate staphylococcal carriage</p>
</li>
<li>
<p>Rifampin combination therapy is also indicated for treatment of serious staphylococcal infections such as osteomyelitis and prosthetic valve endocarditis</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adr">ADR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Imparts a harmless orange color to urine, sweat, tears, and contact lenses (soft lenses may be permanently stained
Occasional may cause rashes, thrombocytopenia, and nephritis
May also cause cholestatic jaundice and occasionally hepatitis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrs-ct">ADRs ct.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs-ct" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5efdc067"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Commonly causes light-chain proteinuria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5efdc067" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>If administered less often than twice weekly, it causes a flu-like syndrome characterized by fever, chills, myalgias, anemia, and thrombocytopenia and sometimes is associated with acute tubular necrosis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Induces most cytochrome P450 isoforms hence increases the elimination of other drugs including:-</p>
<ul>
<li>
<p>methadone</p>
</li>
<li>
<p>anticoagulants</p>
</li>
<li>
<p>cyclosporine</p>
</li>
<li>
<p>some anticonvulsants</p>
</li>
<li>
<p>protease inhibitors</p>
</li>
<li>
<p>Non-nucleoside reverse transcriptase inhibitors etc
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Administration of rifampin results in significantly lower serum levels of these drugs</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="isoniazid">Isoniazid<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#isoniazid" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>â˜ A synthetic agent with a structural similarity to that of pyridoxine</p>
<p><strong>MOA</strong></p>
</li>
<li>
<p>â˜ Inhibits synthesis of mycolic acids (fatty acids), which are essential components of mycobacterial cell walls</p>
<p><strong>Resistance</strong></p>
</li>
<li>
<p>â˜ Is associated with mutations</p>
</li>
</ul>
<p><em>ANTIMYCOBACTERIA 2018 by urbanus mutiso 14/12/2025</em></p>
<p><img src="data:image/jpeg;base64,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" alt="img-1.jpeg"></p>
<ul>
<li>â˜ Readily absorbed from the gastrointestinal tract</li>
<li>â˜ A 300-mg oral dose (5 mg/kg in children) achieves peak plasma concentrations of 3-5 mcg/mL within 1-2 hours</li>
<li>â˜ It diffuses readily into all body fluids and tissues</li>
</ul>
<p>PK ct.</p>
<p>â˜ The concentration in the central nervous system and cerebrospinal fluid ranges between 20% and 100% of simultaneous serum concentrations</p>
<p>â˜ <strong>Metabolism</strong>: Is by acetylation by liver <em>N</em>-acetyltransferase and is genetically determined; some individuals are slow acetylators while others are rapid acetylators</p>
<p>PK ct.</p>
<p>Clearance of isoniazid by rapid
acetylators is usually of no therapeutic
consequence when appropriate doses
are administered daily</p>
<p>Subtherapeutic concentrations may
occur if drug is administered as a once-
weekly dose or incase of malabsorption</p>
<p>ANTIMYCOBACTERIA 2018 by urbanus mutiso 14/12/2025</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="metabolites-and-a-small-amount-of-unchanged-drug-are-excreted-mainly-in-the-urine">Metabolites and a small amount of unchanged drug are excreted mainly in the urine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#metabolites-and-a-small-amount-of-unchanged-drug-are-excreted-mainly-in-the-urine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>The dose need not be adjusted in renal failure</li>
<li>Dose adjustment is not well defined in patients with severe pre-existing hepatic insufficiency</li>
</ul>
<p><em>ANTIMYCOBACTERIA 2018 by urbanus mutiso 14/12/2025</em></p>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Isoniazid is contraindicated if it is the cause of the hepatitis
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Reduction in dose if contemplated should be guided by serum concentrations</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The incidence and severity ADRs are related to dosage and duration of Rx</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-immunologic-reactions">A. IMMUNOLOGIC REACTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-immunologic-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Fever and skin rashes
Drug-induced systemic lupus erythematosus</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b-direct-toxicity">B. DIRECT TOXICITY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-direct-toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Isoniazid-induced hepatitis- risk increase with age, is rare in patients below 20 yrs
Clinical hepatitis with loss of appetite, nausea, vomiting, jaundice, and right upper quadrant pain occurs</p>
<ul>
<li>Risk of hepatitis is greater in alcoholics, during pregnancy and the postpartum period</li>
<li>Development of INH induced hepatitis contraindicates further use of the drug</li>
<li>Central nervous system toxicity: are less common, includes memory loss, psychosis, and seizures</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="29">29<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#29" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Peripheral neuropathy -observed in 10-20% of patients- occur more in slow acetylators and patients with predisposing conditions such as malnutrition, alcoholism, diabetes, AIDS, and uremia
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Occur due to a relative pyridoxine deficiency
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Isoniazid promotes excretion of pyridoxine, and this toxicity is readily</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-include">other include:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-include" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hematologic abnormalities, provocation of pyridoxine deficiency anemia, Tinnitus</p>
<p>Gastrointestinal discomfort</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Ionized can reduce the metabolism of phenytoin, increasing its blood level and toxicity</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="moa">MOA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#moa" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Inhibits mycobacterial arabinosyl transferases an enzyme involved in the polymerization reaction of arabinoglycan, an essential component of the mycobacterial cell wall</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pk">PK<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pk" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Well absorbed from the gut
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> blood level peak is reached in 2-4 hours
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Excretion: About 20% excreted in feces and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> in urine in unchanged form
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> The drug accumulates in renal failure and dose should be reduced by half if creatinine clearance is less than 10 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mL} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mL</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span></p>
<p>â˜ Ethambutol crosses the blood-brain barrier only if the meninges are inflamed</p>
<p>â˜ Concentrations in cerebrospinal fluid are highly variable, ranging from 4% to 64% of serum levels in the setting of meningeal inflammation</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-uses">Clinical uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Usually given as a single daily dose in combination with isoniazid or rifampin
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> A higher dose is recommended for treatment of tuberculous meningitis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypersensitivity to ethambutol is rare
Most common serious ADR is optic neuritis- result in loss of visual acuity and red-green color blindness- a doserelated side effect
(More likely to occur at doses of 25 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> continued for several months)</p>
<p>36</p>
<p>â˜ Periodic visual acuity testing is
desirable if the 25 mg/kg/d dosage is
used</p>
<p>â˜ Relatively contraindicated in children
too young to permit assessment of
visual acuity and red-green color
discrimination</p>
<p>ANTIMYCOBACTERIA 2018 by urbanus mutiso 14/12/2025</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pyrazinamide">PYRAZINAMIDE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pyrazinamide" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>â˜ Stable, and slightly soluble in water</li>
<li>â˜ Inactive at neutral pH,</li>
<li>â˜ Inhibits tubercle bacilli and some other mycobacteria at pH 5.5</li>
</ul>
<p>â˜ The drug is taken up by macrophages and exerts its activity against
mycobacteria residing within the acidic
environment of lysosomes
â˜ It is converted to pyrazinoic acid the
active form of the drug by
mycobacterial pyrazinamidase
â˜ Mechanism of action are unknown</p>
<p>ANTIMYCOBACTERIA 2018 by urbanus mutiso 14/12/2025</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pk">PK<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pk" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Well absorbed from the gastrointestinal tract
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Widely distributed in body tissues, including inflamed meninges
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> The half-life is 8-11 hours
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> The parent compound is metabolized by the liver,</p>
<p>Metabolites are renally cleared; therefore, pyrazinamide should be administered at 25-35 mg/kg three times weekly (not daily) in hemodialysis patients and those in whom the creatinine clearance is less than 30 mL/min</p>
<p>In patients with normal renal function, a dose of 40-50 mg/kg is used for thrice-weekly or twice-weekly treatment regimens.</p>
<ul>
<li>â˜ Pyrazinamide is an important front-line drug used in conjunction with isoniazid and rifampin in short-course (ie, 6-month) regimens as a "sterilizing" agent active against residual intracellular organisms that may cause relapse</li>
<li>â˜ Tubercle bacilli develop resistance to pyrazinamide fairly readily</li>
<li>â˜ Has no cross-resistance with isoniazid or other antimycobacterial drugs</li>
</ul>
<p><em>ANTIMYCOBACTERIA 2018 by urbanus mutiso 14/12/2025</em></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Major ADRs include:</p>
<ul>
<li>Hepatotoxicity</li>
<li>Nausea</li>
<li>Vomiting</li>
<li>Drug fever, and</li>
<li>Hyperuricemia -may provoke acute gouty arthritis</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="streptomycin">STREPTOMYCIN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#streptomycin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> An aminoglycoside
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Penetrates into cells poorly and is active mainly against extracellular tubercle bacilli
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Streptomycin crosses the blood-brain barrier and achieves therapeutic concentrations with inflamed meninges</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-use">Clinical use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Used when an injectable drug is needed or desirable, principally in individuals with severe, possibly life-threatening forms of tuberculosis, e.g. meningitis and disseminated disease, and in treatment of infections resistant to other drugs</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="retreatment">Retreatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#retreatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> For patients who have previously been treated for TB for more than one month including those who:</p>
<ul>
<li>Have relapsed after successful previous treatment, or</li>
<li>Those who defaulted from previous treatment or</li>
<li>Failed previous treatment, with sputum smears remaining positive at 4/5, 6/8 month</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="initial-rx">Initial rx<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#initial-rx" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2rhze-4rh-or-br-2rhze-4rhe">2RHZE+4RH OR &lt;br&gt; 2RHZE+ 4RHE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2rhze-4rh-or-br-2rhze-4rhe" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="retreatment-regime">Retreatment Regime<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#retreatment-regime" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="intensive-phase">Intensive phase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#intensive-phase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Daily treatment with appropriate patient support for two months with:</p>
<ul>
<li>Streptomycin (S) + Ethambutol (E) + Rifampicin (R) + Isoniazid (H) + Pyrazinamide (Z)</li>
</ul>
</li>
<li>
<p>Daily treatment with appropriate patient support for one month with:</p>
<ul>
<li>Ethambutol (E) + Rifampicin (R) + Isoniazid (H)</li>
<li>Pyrazinamide (Z)</li>
</ul>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="continuation-phase">Continuation phase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#continuation-phase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>â˜ Daily treatment with appropriate patient support for <strong>five months</strong> with Ethambutol (E) + Rifampicin (R) + Isoniazid (H)</p>
</li>
<li>
<p>â˜ <strong>The whole regime is Abbreviated as</strong></p>
<ul>
<li>2SRHZE/1RHZE/5RHE <em>(For both Intensive and continuation)</em></li>
</ul>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-tb-in-pregnancy">Treatment of TB in pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-tb-in-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Like most drugs anti-TB drugs have not been specifically studied in pregnancy
There is always some risk of teratogenicity with any drugs especially when the drug is given in the first trimester
In general, pregnancy should be avoided during anti TB treatment.</p>
<p>â˜ TB should be treated with a full complement of anti-TB drugs</p>
<p>â˜ useful to give Pyridoxine with Isoniazid to avoid the small risk of damaging the infant's nervous system</p>
<p>â˜ Streptomycin should not be used in pregnancy because it may cause deafness in the infant</p>
<p>Aminoglycosides used in treatment of drug resistant TB like: Kanamycin, Amikacin and Capreomycin and the thioamides: Ethionamide and Prothionamide should not be used in pregnancy because of associated ototoxity</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-resistant-tb">Drug resistant TB<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-resistant-tb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drug Resistance is classified in two ways:
1)Based on exposure
2)Based on the type of resistance expressed by the TB bacilli</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-based-on-exposure">Classification based on exposure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-based-on-exposure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Primary resistance- if there was definitely no previous treatment.</li>
<li>Initial resistance-when previous treatment cannot definitely be excluded.</li>
<li>Acquired resistance-if there is a definite history of previous treatment</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="2-based-on-the-type-of-resistance-expressed-by-the-tb-bacilli">2) Based on the type of resistance expressed by the TB bacilli<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-based-on-the-type-of-resistance-expressed-by-the-tb-bacilli" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>Mono-resistant TB- TB which is resistant to one first line anti -TB Drug.</p>
</li>
<li>
<p>Poly resistant TB- TB which is resistant to more than one anti-TB drug except both Rifampicin and Isoniazid.</p>
</li>
<li>
<p>Multi-Drug Resistant (MDR) TB- resistance to both Rifampicin and Isoniazid</p>
</li>
<li>
<p>Extensively drug Resistant (XDR) TB- is MDR-TB (i.e further to being resistant to Rifampicin and Isoniazid) it is also resistant to any fluoroquinolone and one or more of the following injectable drugs:Kanamycin, Amikacin and Capreomycin</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-resistance-tb">Drug therapy of resistance TB<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-resistance-tb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Mono-resistant TB
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> When there is resistance to any one only one first line antituberculosis drug
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> Only the offending drug should be substituted;</li>
</ol>
<ul>
<li>Ethambutol replaces Isoniazid</li>
<li>Fluoroquinolone replaces Rifampicin</li>
</ul>
<ol start="2">
<li>Poly-resistant TB
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> When there is resistance to two or more first line anti TB drugs other than both Rifampicin and Isoniazid.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">â–¡</mi></mrow><annotation encoding="application/x-tex">\square</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.675em;"></span><span class="mord amsrm">â–¡</span></span></span></span></span> The two offending drugs should be replaced</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="3-mdr-tb">3. MDR TB<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-mdr-tb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul class="contains-task-list">
<li class="task-list-item"><input type="checkbox" disabled=""> This is mycobacteria that is resistant to both Isoniazid and Rifampicin</li>
<li class="task-list-item"><input type="checkbox" disabled=""> Treatment is in two phases</li>
<li class="task-list-item"><input type="checkbox" disabled=""> The intensive and continuation phases</li>
<li class="task-list-item"><input type="checkbox" disabled=""> Intensive phase lasts 6 months</li>
<li class="task-list-item"><input type="checkbox" disabled=""> Continuation phase lasts for 18 months</li>
</ul>
<p><em>ANTIMYCOBACTERIA 2018 by urbanus mutis</em> 14/12/2025</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="extra-pulmonary-mdrtb">Extra-pulmonary MDRTB<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#extra-pulmonary-mdrtb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The treatment strategy is the same as in patients with pulmonary MDR -TB.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-for-mdr-tb">Drugs used for MDR TB<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-for-mdr-tb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>|  First line oral anti TB | 1.Pyrazinamide(Z)
2.Ethambutol(E)
3.Rifampicin(R)
4.Isoniazid(H)  |
| --- | --- |
|  Injectable anti- TB agent | 1.Streptomycin (S)
2.Kanamycin (Km)
3.Amikacin (Am)
4.Capreomycin (Cm)
5.Viomycin (Vi)  |
|  Second line fluoroquinolones | 1. Ciprofloxacin (Cfx)
2.Ofloxacin (Ofx)
3.Levofloxacin (Lfx)
4.Moxifloxacin (Mfx)
5.Gatifloxacin (Gfx)
6.Sparfloxacin  |</p>
<table><thead><tr><th style="text-align: left;">Oral bacteriostatic second- &lt;br&gt; line anti-TB agents</th><th style="text-align: left;">1.Ethionamide (Eto) &lt;br&gt; 2.Protionamide (Pto) &lt;br&gt; 3.Cycloserine (Cs) &lt;br&gt; 4.Terizidone (Trd) &lt;br&gt; 5.P-amino salicylic acid &lt;br&gt; (PAS) &lt;br&gt; 6.Thioacetazone (Th)</th></tr></thead><tbody><tr><td style="text-align: left;">Third line anti-TB agents - &lt;br&gt; have unclear efficacy</td><td style="text-align: left;">1.Clofazimine (Cfz) &lt;br&gt; 2.Amoxicillin/Clavulanate &lt;br&gt; (Amx/Clv) &lt;br&gt; 3.Clarithromycin (Clr)</td></tr></tbody></table>
<p>Standard regimen</p>
<ul>
<li>â˜ 6 Km-Pto-Lfx-Cs-(E/Z) / 18 Pto-Lfx-Cs-(E/Z)</li>
</ul>
<ol>
<li><strong>6 months of:</strong> Kanamycin (injectable), Protionamide, Levofloxacin, Cycloserine &amp; either Ethambutol <strong>or</strong> Pyrazinamide</li>
</ol>
<ul>
<li><strong>plus</strong></li>
</ul>
<ol start="2">
<li><strong>18 months of:</strong> Protionamide, Levofloxacin, Cycloserine &amp; either Ethambutol <strong>or</strong> Pyrazinamide</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiprotozoas">ANTIPROTOZOAS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiprotozoas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>2019</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="introduction">Introduction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#introduction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Common protozoan infections:</li>
<li>Malaria</li>
<li>Amoebiasis</li>
<li>Leishmaniasis</li>
<li>Trypanosomiasis</li>
<li>Trichomoniasis</li>
<li>Giardiasis</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antimalarials">ANTIMALARIALS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antimalarials" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>mr. mutiso</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="introduction">INTRODUCTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#introduction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>A protozoan infection caused by plasmodium</li>
<li>Classified into two as</li>
<li>either uncomplicated or</li>
<li>severe malaria</li>
<li>Management based on the classification</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="life-cycle-of-the-plasmodium">Life cycle of the plasmodium<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#life-cycle-of-the-plasmodium" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Mosquito inject sporozoites into the blood while feeding
Sporozoites are carried by the circulatory system to the liver and invade hepatocytes
An asexual replication known as exoerythrocytic schizogony begin within the hepatocyte
culminates in the production of merozoites which are released into the bloodstream</p>
<p>Merozoites invade erythrocytes &amp; begin to enlarge as a unnucleated cell called the ring trophozoite</p>
<p>Ends with rounds of nuclear division resulting in formation of <strong>schizont</strong></p>
<ul>
<li>
<p>The erythrocyte ruptures &amp; release toxins that bring about the cycle of fever &amp; chills that is characteristic of malaria</p>
</li>
<li>
<p>Merozoites bud from the mature schizont, and are released following rupture of the infected erythrocyte (can re-infect more erythrocytes)</p>
</li>
<li>
<p>Invasion of erythrocytes reinitiates another round of the blood-stage replicative cycle</p>
</li>
<li>
<p>The blood stage is responsible for the pathology associated with malaria</p>
</li>
<li>
<p>Plasmodium enter the sexual phase when some merozoites in the erythrocyted develop into gametocytes, cells that are capable of producing both male and female gametes</p>
</li>
<li>
<p>Erythrocytes containing gametes do not rupture</p>
</li>
</ul>
<p>Gametocytes are incapable of producing gametes within their human host, they only do so when extracted from an infected human host by a mosquito</p>
<ul>
<li>Within the gut of a mosquito, the gametocyte form the male and female gametes</li>
<li>They develop within the mosquito intestinal wall and differentiate into oocytes that produce sporozoites thru repeated cycles of mitotic division</li>
<li>The sporozoites migrate to the salivary gland of the mosquito and re injected into the human blood stream</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-classification">Drug Classification<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs that eliminate developing or dormant liver forms- tissue schizonticides
Those that act on erythrocytic parasitesblood schizonticides
Those that kill the sexual stage and prevent transmission to the mosquito- gametocides
No one agent can reliably effect a radical cure, ie, eliminate both hepatic and erythrocytic stages
Causal prophylactic drugs- capable of preventing erythrocytic infection</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="structural-classification">Structural Classification<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#structural-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>4- aminoquinolones- chloroquine, amodiaquine
8-aminoquinololes-primaquine
Quinoline methanol- quinine, quinidine, mefloquine
Folate antagonists- sulfadoxine pyrimethamine, chlorproguanil, proguanil
5. Amyl alcohol- lumefantrine</p>
<p>Tetracyclines- doxycyline
others: artemisinin, halofantrine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quinine">Quinine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quinine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-use">Clinical Use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Treatment of multidrug-resistant malaria</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-action">Mechanism of action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Quinine complexes with doublestranded DNA to prevent strand separation, resulting in block of DNA replication and transcription to RNA</li>
<li>Quinine is only a blood schizonticide</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrs">ADRs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cinchonism, symptoms ,include:
Gastrointestinal distress,
Headache,
Vertigo,
Blurred vision, and
Tinnitus
Severe overdose results in disturbances in cardiac conduction</p>
<p>Hematotoxic effects: hemolysis in glucose-6phosphate dehydrogenase (G6PD)-deficient patients</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="blackwater-fever-intravascular-hemolysis-is-rare-and-but-fatal-complication-in-quinine-sensitized-persons">Blackwater fever (intravascular hemolysis) : is rare and but fatal complication in quinine-sensitized persons<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#blackwater-fever-intravascular-hemolysis-is-rare-and-but-fatal-complication-in-quinine-sensitized-persons" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antifolate-drugs">Antifolate Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antifolate-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Includes</p>
<ul>
<li>Pyrimethamine</li>
<li>Proguanil</li>
<li>Sulfadoxine</li>
<li>Dapsone</li>
</ul>
<p>All are absorbed orally
All are excreted in the urine, partly in unchanged form</p>
<ul>
<li>Proguanil has a shorter half-life (12-16 h) than other drugs in this subclass (half-life <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>100</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;100 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">100</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span> )</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="sulfonamides-act-as-an-antimetabolites-of-paba-and-block-folic-acid-synthesis-in-certain-protozoans-by-inhibiting-dihydropteroate-synthase">Sulfonamides act as an antimetabolites of PABA and block folic acid synthesis in certain protozoans by inhibiting dihydropteroate synthase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sulfonamides-act-as-an-antimetabolites-of-paba-and-block-folic-acid-synthesis-in-certain-protozoans-by-inhibiting-dihydropteroate-synthase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Pyrimethamine and cycloguanil (active form of Proguanil) are selective inhibitors of protozoan dihydrofolate reductases</li>
<li>The combination of pyrimethamine with sulfadoxine has synergistic antimalarial effects through the <strong>sequential blockade</strong> of <strong>2 steps in folic acid synthesis</strong></li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-use">Clinical Use<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-use" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The antifolates are blood schizonticides that act mainly against <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span> falciparum
Pyrimethamine with sulfadoxine in fixed combination (Fansidar) is used in the treatment of chloroquine-resistant forms of this <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi></mrow><annotation encoding="application/x-tex">p</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span></span></span></span></span> falciparum although with a slow onset of action</p>
<ul>
<li>Proguanil with atovaquone in fixed combination (Malarone) can be used (daily) for chemoprophylaxis of chloroquine-resistant malaria and is also protective against mefloquine-resistant falciparum strains</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="toxicity">Toxicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Toxic effects of sulfonamides include:</p>
<ul>
<li>Skin rashes</li>
<li>Gastrointestinal distress</li>
<li>Hemolysis</li>
<li>Kidney damage</li>
<li>Pyrimethamine may cause folic acid deficiency when used in high doses</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interaction">Drug interaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Result from competition for plasma protein binding</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="artesunate-artemether-dihydroartemisinin">Artesunate, Artemether, Dihydroartemisinin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#artesunate-artemether-dihydroartemisinin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These artemisinin derivatives are metabolized in the food vacuole of the parasite forming toxic free radicals</p>
<ul>
<li>Artemisinins are blood schizonticides</li>
<li>Active against P falciparum, including multidrug-resistant strains</li>
<li>Given orally but an IV formulation available for severe infections</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-uses">Clinical uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Treatment of malaria- best in combination with other</li>
<li>Not used for chemoprophylaxis because of their short half-lives of 1-3 h</li>
<li>Are the only drugs reliably effective against quinine-resistant strains</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-effects">Adverse effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>GIT disturbances: Nausea, vomiting, and diarrhoea</li>
<li>Their safety in pregnancy has not been established but can be used.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="recommended-drugs-and-dosages">Recommended Drugs and Dosages<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#recommended-drugs-and-dosages" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="first-line-treatment">First Line Treatment:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#first-line-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Artemether + Lumefantrine (AL)
<ul>
<li>6 doses given over 3 days</li>
</ul>
</li>
<li>Below 5 Kg
<ul>
<li>Half a tablet of AL or Dispersible AL</li>
</ul>
</li>
<li>Second Line Treatment
<ul>
<li>Dihydroartemisinin+Piperaquine (DHAP)</li>
<li>3 doses given over 3 days</li>
</ul>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dosing-schedule-for-al">Dosing Schedule for AL<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosing-schedule-for-al" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="weight-5-to-15-kgs">WEIGHT: 5 TO &lt;15 KGs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#weight-5-to-15-kgs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th>DAY</th><th>HOURS</th><th></th><th></th></tr></thead><tbody><tr><td></td><td>0 HRS</td><td>8 HRS</td><td>12 HRS</td></tr><tr><td>ONE</td><td>1</td><td>1</td><td></td></tr><tr><td>TWO</td><td>1</td><td></td><td>1</td></tr><tr><td>THREE</td><td>1</td><td></td><td>1</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="weight-15-to-25-kgs">WEIGHT: 15 TO &lt;25 KGs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#weight-15-to-25-kgs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th>DAY</th><th>HOURS</th><th></th><th></th></tr></thead><tbody><tr><td></td><td>0 HRS</td><td>8 HRS</td><td>12 HRS</td></tr><tr><td>ONE</td><td>2</td><td>2</td><td></td></tr><tr><td>TWO</td><td>2</td><td></td><td>2</td></tr><tr><td>THREE</td><td>2</td><td></td><td>2</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="weight-25-to-35-kgs">WEIGHT: 25 TO &lt;35 KGs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#weight-25-to-35-kgs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th>DAY</th><th>HOURS</th><th></th><th></th></tr></thead><tbody><tr><td></td><td>0 HRS</td><td>8 HRS</td><td>12 HRS</td></tr><tr><td>ONE</td><td>3</td><td>3</td><td></td></tr><tr><td>TWO</td><td>3</td><td></td><td>3</td></tr><tr><td>THREE</td><td>3</td><td></td><td>3</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="weight-35-kgs">WEIGHT: &gt;35 KGs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#weight-35-kgs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th>DAY</th><th>HOURS</th><th></th><th></th></tr></thead><tbody><tr><td></td><td>0 HRS</td><td>8 HRS</td><td>12 HRS</td></tr><tr><td>ONE</td><td>4</td><td>4</td><td></td></tr><tr><td>TWO</td><td>4</td><td></td><td>4</td></tr><tr><td>THREE</td><td>4</td><td></td><td>4</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-suspected-treatment-failure">Management of suspected treatment failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-suspected-treatment-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treat-with-dihydroartemisinin-piperaquine">Treat with Dihydroartemisinin-Piperaquine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treat-with-dihydroartemisinin-piperaquine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Treat confirmed cases</li>
<li>Malaria microscopy should be used to confirm (RDTs not recommended)</li>
<li>In facilities with no microscopy patients with suspected treatment failure should be referred</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-severe-malaria">Management of severe malaria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-severe-malaria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Recommended treatment is parenteral artesunate</p>
<ul>
<li>Iv the preferred route but IM can be used where IV is not feasible</li>
<li>Quinine used in absence of artesunate</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="administer-treatment-in-the-following-order-of-preference-depending-on-availability">Administer treatment in the following order of preference depending on availability:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#administer-treatment-in-the-following-order-of-preference-depending-on-availability" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul class="contains-task-list">
<li class="task-list-item"><input type="checkbox" disabled=""> IM/IV artesunate</li>
<li class="task-list-item"><input type="checkbox" disabled=""> Rectal Artesunate (suppositories)</li>
<li class="task-list-item"><input type="checkbox" disabled=""> IM/IV Quinine</li>
<li class="task-list-item"><input type="checkbox" disabled=""> IM Artemether (only given IM)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="artesunate-administration">Artesunate administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#artesunate-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Dissolve artesunic powder with 5% sodium bicarbonate (provided with vial)
Dilute resultant solution with 5mls normal saline(provided with vial) or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose
Administer <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.4 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> stat by slow IV
Repeat <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.4 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> at 12 hrs and 24 hrs
Thereafter administer <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.4 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> daily until patient can take orally, then
Give a complete course of AL</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quinine-administration-in">Quinine administration in<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quinine-administration-in" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="loading-dose-of-20mg-kg20-mathrm-mg-mathrm-kg-20mg-kg-in-15ml-kg15-mathrm-ml-mathrm-kg-15ml-kg-of-5-5-5-dextrose-or-normal-saline-to-run-over-4-hours">Loading dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose or normal saline to run over 4 hours<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#loading-dose-of-20mg-kg20-mathrm-mg-mathrm-kg-20mg-kg-in-15ml-kg15-mathrm-ml-mathrm-kg-15ml-kg-of-5-5-5-dextrose-or-normal-saline-to-run-over-4-hours" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Omit loading dose if any quinine has been given in the previous 24 hours 8 hours from commencement of initial dose, give <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> quinine in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose or normal saline to run over 4 hours</p>
<p>Repeat <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> infusion every 8 hours until the patient is able to sit up and take oral medication</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dose-of-im-quinine">Dose of IM quinine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dose-of-im-quinine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Quinine must be diluted to a maximum of</p>
<ul>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> in children</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> in adults before IM administration</li>
</ul>
<p>Loading dose for IM quinine is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in ALL age groups ( to a maximum of 1200 mg )</p>
<p>A maximum of 3 ml to be injected at one site</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="im-artemether">IM Artemether<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#im-artemether" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>IM artemether is fat soluble
It is provided in dilution form</p>
<ul>
<li>Administer as a start dose</li>
<li>Administer IM 3.2mg/kg/body wt od 3/7</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quinine-administration-in-adults">Quinine administration in adults<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quinine-administration-in-adults" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Loading dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (maximum of 1200 mg )in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose or normal saline to run over 4 hours</p>
<ul>
<li>Omit loading dose if any quinine has been given in the previous 24 hours</li>
<li>Maintain with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (maximum of 600 mg ) infusion 8 hourly until the patient is able to take oral medication</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="follow-on-treatment-after-iv-quinine">Follow on treatment after IV quinine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#follow-on-treatment-after-iv-quinine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Once all patients are able to take oral medication:</p>
<ul>
<li>Give a full course of artemetherlumefantrine</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="or">OR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#or" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Continue oral quinine at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (max 600 mg ) 8 hourly for a total of 7 days of treatment</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="supportive-treatment">Supportive treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#supportive-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypoglycaemia - IV or oral glucose (10% glucose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> )
Convulsions
diazepam <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.3 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> IV or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> rectally</p>
<ul>
<li>Phenytoin or phenobarbitone</li>
</ul>
<p>Severe anaemia - transfuse
Fluid and electrolyte balance
Fever and nursing care</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-uncomplicated-malaria-in-pregnancy">Treatment of uncomplicated malaria in pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-uncomplicated-malaria-in-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="first-trimester">First trimester<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#first-trimester" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Oral quinine - 7 days
Avoid AL in the first trimester (Concerning safety)
Do not withhold AL in the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>1</mn><mtext>st&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1^{\text {st }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7936em;"></span><span class="mord"><span class="mord">1</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7936em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">st&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> trimester if quinine is not available</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1fc27aed"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mtext>nd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">2^{\text {nd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">nd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> trimester<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1fc27aed" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>AL</li>
</ul>
<p>Oral Quinine if AL not available</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="severe-malaria-in-pregnancy">Severe malaria in pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#severe-malaria-in-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>In all suspected cases of severe malaria</li>
<li>parasitological confirmation recommended</li>
<li>If no parasitological diagnosis or delay is anticipated, treat for severe malaria on clinical grounds</li>
<li>****Remember severe malaria can be confused for eclampsia</li>
<li>parameters that differentiate: temp, Bp, spleen enlarged in malaria, jaundice in malariotriprotozoans by u mutiso</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-severe-malaria">Treatment of severe malaria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-severe-malaria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>IV Artesunate</li>
<li>IV quinine</li>
<li>5% dextrose preferred infusion solution when infusing IV Quinine</li>
<li>NB*Rx should be started in the facility where mother present as you wait to refer</li>
<li>Administer IM artesunate, artemether or IM quinine (add glucose if quinine is used)</li>
</ul>
<p>Accompany patient on referral</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quinine-administration">Quinine administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quinine-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Loading dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (maximum of 1200 mg ) in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose</p>
<ul>
<li>If 5% dextrose is not available, use normal saline</li>
<li>Omit loading dose if any quinine has been given in the previous 24 hours</li>
<li>Maintain with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (maximum of 600 mg ) infusion 8 hourly until the patient is able to take oral medication</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="follow-up-treatment-after-iv-quinine">Follow up treatment after IV quinine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#follow-up-treatment-after-iv-quinine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="once-all-patients-are-able-to-take-oral-medication">Once all patients are able to take oral medication:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#once-all-patients-are-able-to-take-oral-medication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Give a full course of artemetherlumefantrine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="or">OR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#or" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Continue oral quinine at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> (max 600 mg ) 8 hourly for a total of 7 days of treatment</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="major-highlights">Major highlights<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#major-highlights" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Confirmatory diagnosis of all suspected malaria cases is recommended in all age groups.</li>
<li>AL is the first line of treatment of uncomplicated malaria</li>
<li>Dihydroartemisinin + piperaquine is the 2nd line treatment for uncomplicated malaria</li>
<li>Artesunate is the 1st line for treatment of severe malaria</li>
</ul>
<p>It should be given iv but IM allowed in centers where Ivs cannot be fixed
Quinine is an alternative to artesunate in severe malaria
Loading dose of Quinine is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in all age groups
Frequency in administration of Quinine for children has changed from 12 hourly to 8hourly</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="major-highlights">Major highlights<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#major-highlights" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Currently artesunate injection is the recommended treatment for severe malaria</p>
<p>P vivax has dormant liver stages that may not cured by artesunate</p>
<p>Primaquine used to achieve radical cure of the dormant liver stages and prevent relapse</p>
<ul>
<li>Malaria in pregnancy (MIP)</li>
<li>Minimum of 2 doses of SP for IPT</li>
<li>IPTp is administered 4 weeks apart till delivery</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiprotozoan-drugs">Antiprotozoan drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiprotozoan-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chemotherapy-for-amoebiasis">Chemotherapy for amoebiasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-for-amoebiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Metronindazole/ tinindazole</li>
<li>Diloxanide furoate</li>
<li>Paramomycin</li>
<li>Chloroquin</li>
<li>Emetine</li>
<li>Dehydroemetine</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="classification-of-anti-amoeba">Classification of anti-amoeba<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classification-of-anti-amoeba" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Classified into mixed, luminal or systemic amebicides</li>
<li>Mixed agents:</li>
<li>Are effective against both luminal and systemic forms of amoeba</li>
<li>Include:</li>
<li>Metronindazole &amp; tinindazole</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="luminal-amoebicides">Luminal amoebicides<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#luminal-amoebicides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>They act on parasites in the lumen of the bowels</li>
<li>Include:</li>
<li>Diloxanide furoate</li>
<li>Tetracycline</li>
<li>paramomycin</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="systemic-amoebicides">Systemic amoebicides<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#systemic-amoebicides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Effective against parasites in the systems</li>
<li>Include:</li>
<li>Emetine</li>
<li>Dehydroemetine</li>
<li>Chloroquine</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="metronindazole">Metronindazole<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#metronindazole" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The agent of choice for treatment of infections by entamoeba histolytica, giardia lamblia and trichomonas vaginalis
Used in treatment of infections by:</p>
<ul>
<li>Anaerobic cocci</li>
<li>Anaerobic gram negative bacilli like bacteriodes</li>
<li>Anaerobic gram +ve bacilli like clostridia</li>
<li>Treatment of brain abscesses caused by other organisms</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pk">PK<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pk" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Completely and rapidly absorbed orally
Usually administered with luminal amoebicides
Well distributed throughout the body tissues and fluids</p>
<ul>
<li>Therapeutic levels achieved in vaginal and seminal fluids, saliva and CSF</li>
<li>Metabolized in the liver through oxidation followed by glucolonidation</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-uses">Clinical uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-amebiasis">A. AMEBIASIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-amebiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Metronidazole or tinidazole is the drug of choice in the treatment of all tissue infections with E histolytica.
They are not reliably effective against luminal parasites and so must be used with a luminal amebicide to ensure eradication of the infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-giardiasis">B. GIARDIASIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-giardiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Metronidazole is the treatment of choice for giardiasis. The dosage for giardiasis is much lower and the drug thus better tolerated than that for amebiasis.</p>
<p>Efficacy after a single treatment is about 90%. Tinidazole is equally effective</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrs">ADRs.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>GIT disturbances: nausea, vomiting, epigastric distress, &amp; abdominal cramps</li>
<li>Unpleasant metallic taste</li>
<li>Oral moniliasis (yeast infections)</li>
<li>Neurotoxicity- vertigo, dizziness, numbness, paresthesia in peripheral nervous system</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diloxanide-furoate">Diloxanide furoate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diloxanide-furoate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drug of choice in treatment of asymptomatic passers or cyst
For treatment of intestinal amoebicides
The drug is hydrolyzed in the intestinal mucosa and the diloxanide is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> absorbed</p>
<ul>
<li>The unabsorbed drug is the active amebicide</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrs">ADRs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Flatulence</li>
<li>Dryness of the mouth</li>
<li>Pruritus</li>
<li>Urticaria</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="contraindications">Contraindications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contraindications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Pregnancy</li>
</ul>
<p>Children under 2 years of age</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chloroquine">Chloroquine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chloroquine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Used in conjunction with metronindazole, and diloxanide furoate to treat and prevent amoebic liver disease/abscess</li>
<li>Eliminate trophozoites in liver abscesses but also useful in treatment of liver amoebicides</li>
<li>Also effective in treatment of malaria</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="emetine">Emetine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#emetine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Their use is limited by their toxicities
Close clinical supervision needed with their use
ADR</p>
<ul>
<li>Pain at site of injection</li>
<li>Transient nausea</li>
<li>Cardiotoxicity- arrhythmias, congestive heart failure</li>
<li>Neuromuscular weakness</li>
</ul>
<p>Dizziness &amp; rashes</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-leishmaniasis">Treatment of Leishmaniasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-leishmaniasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sodium-stibogluconate">Sodium stibogluconate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sodium-stibogluconate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>MOA: inhibit glycolysis in the parasite</li>
<li>Not absorbed after oral administration, therefore must be administered parenterally</li>
<li>Well distributed in the extravascular compartments</li>
<li>Undergo minimal metabolism</li>
</ul>
<p>ANTIPROTOZOANS BY u mutiso
Excreted via urine</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrs">ADRs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Pain at the injection site</li>
<li>Gastrointestinal upset</li>
<li>Cardiac arrhythmias</li>
<li>Renal and hepatic function should be periodically monitored</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="trypanosomiasis">Trypanosomiasis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#trypanosomiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>There are of two types</li>
<li>African type and the American type- cause sleeping sickness</li>
<li>The causative organism live &amp; grow in the blood; In latter stages it invade the CNS- brain and spinal cord</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used">Drugs used<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Melarsoprol</li>
<li>Pentamidine</li>
<li>Nifurtimox</li>
<li>Suramin</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pentamidine">Pentamidine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pentamidine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Only administered parenterally
Leaves the circulation rapidly
Has an initial half-life of about 6 hours
Highly bound to tissue, thus accumulates and is eliminated very slowly
Has a terminal elimination half-life of about 12 days
The drug can be detected in urine 6 or more weeks after treatment
Only trace appear in the central nervous system, therefore not effective against central nervous system African trypanosomiasis</p>
<ul>
<li>Pentamidine can also be inhaled as a nebulized powder for the prevention of pneumocystosis.</li>
<li>Absorption into the systemic circulation after inhalation appears to be minimal.</li>
<li>Mechanism of action is unknown.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-uses">Clinical uses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>An alternative to suramin for the early hemolymphatic stage of disease caused by african trypanosomiasis</li>
<li>An alternative to sodium stibogluconate in the treatment of visceral leishmaniasis</li>
<li>Well-established alternative therapy for pulmonary and extra-pulmonary disease caused by P jiroveci (seprin, preferred as it has less toxicities)</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrs">ADRs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Rapid intravenous administration can lead to severe hypotension, tachycardia, dizziness, and dyspnea; the drug should be administered slowly (over 2 hours) and patients should be recumbent and monitored closely during treatment.</p>
<ul>
<li>IM administration- pain at the injection site is common and sterile abscesses may develop</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adr-ct">ADR ct.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adr-ct" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypoglycemia due to inappropriate insulin release often appears 5-7 days after RX start. May be followed by hyperglycemia</p>
<ul>
<li>Reversible renal insufficiency</li>
<li>Rash, fever,</li>
<li>Metallic taste</li>
<li>Gastrointestinal symptoms</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrs-ct">ADRs ct.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs-ct" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Abnormal liver function tests
Hypocalcaemia
Thrombocytopenia
Hallucinations
Cardiac arrhythmias</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="suramin">SURAMIN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#suramin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>The first-line therapy for early hemo-lymphatic African trypanosomiasis</li>
<li>Does not enter the CNS therefore not effective against advanced disease</li>
<li>Mechanism of action is unknown</li>
<li>200 mg intravenous test dose given before treatment start</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pk">Pk<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pk" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="administered-iv">Administered IV<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#administered-iv" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="tightly-bound-to-protein">Tightly bound to protein<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tightly-bound-to-protein" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Short initial half-life but a terminal elimination half-life of about 50 days</li>
<li>Slowly cleared via the kidney</li>
<li>Combination therapy with pentamidine may improve efficacy</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrs">ADRs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Immediate reactions can include fatigue, nausea, vomiting, and, more rarely, seizures, shock, and death
Later reactions include fever, rash, headache, paresthesias, neuropathies, renal abnormalities including proteinuria, chronic diarrhea, hemolytic anemia, and agranulocytosis
NB Also be used for chemoprophylaxis against African trypanosomiasis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="melarsoprol">MELARSOPROL<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#melarsoprol" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The first-line therapy for advanced central nervous system African trypanosomiasis.
Rapidly excreted after IV administration
Clinically relevant concentrations accumulate in the central nervous system within 4 days.
Administered as a slow intravenous infusion at a dosage of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">3.6 \mathrm{mg} / \mathrm{kg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span> for 3-4 days, with repeated courses at weekly intervals if needed</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrs">ADRs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Is extremely toxic
Its use only justified only by the severity of advanced trypanosomiasis and the lack of available alternatives
Immediate adverse effects include fever, vomiting, abdominal pain, and arthralgias
Reactive encephalopathy that generally appears within the first week of therapy in 5-10% of patients probably due to disruption of trypanosomes in the central nervous system.</p>
<ul>
<li>Common consequences of the encephalopathy include cerebral edema, seizures, coma, and death.</li>
</ul>
<p>Renal and cardiac disease and hypersensitivity reactions</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nifurtimox">NIFURTIMOX<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nifurtimox" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Nifurtimox is the most commonly used drug for American trypanosomiasis (Chagas' disease</p>
<ul>
<li>Well absorbed after oral administration and eliminated with a plasma half-life of about 3 hours</li>
<li>Adverse effects include: nausea, vomiting, abdominal pain, fever, rash, restlessness, insomnia, neuropathies, and seizures</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chemotherapy-for-toxoplasmosis">Chemotherapy for toxoplasmosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chemotherapy-for-toxoplasmosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pyrimethamine">Pyrimethamine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pyrimethamine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>